New surgical method for ovarian cancer lights up lesions
Mayo Clinic scientists are shining light on ovarian cancer. A study published in 2022 in the Journal of Clinical Oncology explored the use of fluorescence-guided surgery to treat epithelial ovarian cancer, the most common type of ovarian cancer. Fluorescence-guided surgery uses fluorescence imaging to light up cancerous tissue, giving surgeons a better view of tumors and cancer cells. This makes cancer removal more thorough and accurate. "It was really exciting to be part of fluorescence-guided surgery," says Kristina… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 30, 2023 Category: Databases & Libraries Source Type: news
What Are Treatments for Recurrent Respiratory Papillomatosis?
Discussion
Human papilloma virus (HPV) is a member of the Papillomaviridae virus family with over a 150 different subtypes. HPV can cause cervical, genital and respiratory tract papillomas. HPV is often benign but can cause anogenital, cervical and head and neck cancers.
Recurrent respiratory papillomatosis (RRP) is uncommon but can cause significant morbidity while awaiting the body’s immune system to respond. There is a juvenile and adult form, and the incidence varies between 2-4/100,000 in the pediatric population. The juvenile form frequently occurs between 3.6-6 years of age and in general the younger the patie...
Source: PediatricEducation.org - July 31, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Janssen Marks First Approval Worldwide for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
BEERSE, Belgium, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for AKEEGA® (niraparib and abiraterone acetate [AA]), in the form of a dual action tablet (DAT), given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.2Prostate cancer is the most common cancer in men in Europe, and the sixth-highest cause of cancer-related death worldwide.1...
Source: Johnson and Johnson - April 21, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Patients Needed for New Mesothelioma Clinical Trial
A new investigational drug for mesothelioma can now begin human trials after it was granted fast-track designation by the U.S. Food and Drug Administration last week. The novel treatment, SnyKIR-110, is a T-cell therapy designed to treat patients with mesothelioma, cholangiocarcinoma (bile duct cancer) and ovarian cancer.Â
“We are thrilled to receive fast-track designation from the FDA,” said Dr. Bryan Kim, co-founder and CEO of Verismo Therapeutics. “This designation is an important milestone in our efforts to bring this potentially life-saving drug to patients who are in need of new treatment option...
Source: Asbestos and Mesothelioma News - April 19, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Lifetime Ovulatory Years Linked to Epithelial Ovarian Cancer
WEDNESDAY, March 1, 2023 -- Lifetime ovulatory years (LOY) are associated with the risk for epithelial ovarian cancer (EOC), according to a study published online Jan. 23 in the Journal of the National Cancer Institute.
Zhuxuan Fu, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2023 Category: Pharmaceuticals Source Type: news
Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations
RARITAN, N.J., February 28, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT), plus prednisone, for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). If approved, this will be the first DAT formulation available in the U.S. to patients with mCRPC with BRCA mutations, which are a type of homologous recombination repair (HRR) gene alt...
Source: Johnson and Johnson - March 1, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Receives Positive CHMP Opinion for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
BEERSE, Belgium, 24 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for AKEEGA® (niraparib and AA), in the form of a DAT, given with P or prednisolone, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.[1]Niraparib is a highly selective poly adenosine diphosphate-ribose polymerase (PARP) inhibi...
Source: Johnson and Johnson - February 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, February 16, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinica...
Source: Johnson and Johnson - February 16, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FR α positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 14, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Combo Therapy Shows Promise in Advanced Thymic Epithelial Tumors
(MedPage Today) -- Treatment with avelumab (Bavencio) plus axitinib (Inlyta) showed promising efficacy and safety in patients with unresectable or metastatic type B3 thymoma and thymic carcinoma, according to a single-arm phase II study.
Among... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 4, 2022 Category: Hematology Source Type: news
Blood Protein Might Predict Future Risk of Diabetes, Cancer
FRIDAY, Aug. 5, 2022 -- Elevated levels of a specific protein appear to be linked to an increased risk of developing diabetes and dying from cancer, a new study finds.
High levels of prostasin -- mainly found in epithelial cells, which line the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 5, 2022 Category: General Medicine Source Type: news
Toronto Cancer Center Hosts SMARTEST Mesothelioma Clinical Trial
Princess Margaret Cancer Centre in Toronto recently opened a first-of-its-kind clinical trial that hopes to build on earlier pioneering efforts to turn pleural mesothelioma into a more manageable, potentially survivable disease. Expectations are high.
This single-center phase II clinical trial is named SMARTEST, and follows in the wake of earlier mesothelioma trials SMART and SMARTER in Toronto. SMARTEST is an acronym for Surgery for Mesothelioma After Radiation Therapy using Exquisite Systemic Therapy.
“The hope is that we find an effective therapy with little toxicity. That’s the dream for every cancer doctor,â...
Source: Asbestos and Mesothelioma News - June 28, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
